Survivors of Hodgkin Lymphoma at Increased Risk for Head and Neck Cancer
the Cancer Therapy Advisor take:
Survivors of Hodgkin Lymphoma with squamous cell carcinoma (HL-SCC) are more likely to develop salivary and non salivary head and neck cancer (HNC) after HL than those patients with a first primary SCC, according to a journal article published online in Cancer.
Data from the Surveillance, Epidemiology, and End Results (SEER) database for 1973 through 2011 was used to analyze survivors of HL who developed HCN as a secondary malignancy. These patients were then compared with patients with first primary HCN.
Observed-to-expected ratios were calculated for SCC among patients with HL (1.73; 95% CI, 1.36-2.16; P<0.05) and for SGC (8.56; 95% CI, 5.82-12.15; P<0.05).
Patient history of HL was determined to be an adverse prognostic fact for patient survival for SCC (HR = 1.37; 95% CI: 1.08, 1.73; P=0.009) but not for SGC (HR = 1.21; 95% CI: 0.82, 1.79; P=0.34). Increased risk of mortality in patients with HL-SCC appears to be associated with the deaths from HL and secondary malignancies diagnosed after SCC.
The study suggests that survivors of HL should have regular head and neck examinations and clinicians should be aware of patients’ increased risk for developing HCN after HL.
Survivors of HL-SCC are more likely to develop salivary and non salivary head and neck cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Massage and Cancer
- Pembrolizumab May Lead to Favorable Long-Term Outcomes in Head and Neck Cancer
- Biomarker-Based Blood Test May Extend Reach of CT Screening for Certain Lung Cancers
- Next-Generation Sequencing Adds Value by Detecting More Mutations Than Polymerase Chain Reaction in Melanoma
- Tucatinib May Be A Safe, Novel Treatment for ERBB2/HER2-Positive Breast Cancer